Tryptophan

證據等級: L5

預測適應症: 8 個

Tryptophan: From Nutritional Supplement to Restless Legs Syndrome

One-Sentence Summary

Tryptophan is an essential amino acid and serotonin precursor with no current formal drug indication or active market authorization — historically it was marketed as an over-the-counter sleep and mood aid before a 1989 contamination-related withdrawal. The TxGNN model predicts it may be effective for Restless Legs Syndrome (RLS), with 8 relevant publications (including two small 1980s clinical studies) but no registered clinical trials, and the underlying mechanism is not without controversy.

Quick Overview

Item	Content
Original Indication	No formal approved drug indication on record (historically used OTC as a sleep/mood nutritional supplement)
Predicted New Indication	Restless Legs Syndrome
TxGNN Prediction Score	99.72%
Evidence Level	L3
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for tryptophan (DrugBank MOA field is a data gap). Based on known pharmacology, tryptophan is the metabolic precursor of 5-hydroxytryptophan (5-HTP), which is converted to serotonin and subsequently to melatonin. This serotonin/melatonin axis is the reason tryptophan was historically marketed as an OTC aid for sleep and mood — it has no other formally recognized indication, which is why no “original indication” can be cited here.

RLS pathophysiology is thought to involve dysregulation of both the dopaminergic and serotonergic systems, which is the biological basis for TxGNN’s high prediction score: two small clinical studies from the 1980s (PMID 3953904, 3659737) directly tested L-tryptophan or its metabolites in RLS/periodic limb movement patients and reported some symptomatic benefit.

However, the mechanistic story is not clean. A 2020 pharmacovigilance study (PMID 32546134) found that antidepressants which increase synaptic serotonin (SSRIs) are associated with inducing or worsening RLS symptoms — the opposite direction from what tryptophan supplementation would be expected to produce if the “more serotonin improves RLS” hypothesis were correct. This internal contradiction means the mechanistic rationale should be treated as a hypothesis requiring further clarification, not an established pathway.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
3953904	1986	Open-label clinical study	The American Journal of Psychiatry	Early open-label study reporting symptomatic improvement in RLS patients treated with L-tryptophan
3659737	1987	Clinical study	Sleep	Compared periodic leg movements under L-dopa, 5-HTP, and L-tryptophan, providing early comparative mechanistic data
32546134	2020	Pharmacovigilance cohort	BMC Psychiatry	Global pharmacovigilance analysis found serotonin-increasing antidepressants (SSRIs) associated with drug-induced movement disorders including RLS — a finding that runs counter to the tryptophan-improves-RLS hypothesis
33836477	2021	Systematic review/meta-analysis	Sleep Medicine Reviews	Found elevated tryptophan levels and altered dopamine turnover associated with RLS in chronic liver disease patients — an associative, not interventional, link
1305630	1992	Review	The International Journal of Neuroscience	General review of L-tryptophan’s role in serotonin-related neuropsychiatric and motor conditions
2881477	1987	Review	American Family Physician	General review of insomnia diagnosis and treatment, mentioning tryptophan among historical options; not RLS-specific
36897462	2023	Case report	Neurological Sciences	Case report of RLS in a patient with DNAJC12-related dopaminergic/serotonergic deficiency, an inherited metabolic disorder unrelated to tryptophan supplementation
1777530	1991	Case report	Biological Psychiatry	Case report of lithium-induced RLS; no direct tryptophan therapeutic data

Safety Considerations

Please refer to the package insert for safety information. Note that key warnings, contraindications, and drug-interaction data for tryptophan are currently unavailable in this evidence pack — this is flagged as a blocking data gap that prevents a formal safety pre-assessment (see Conclusion below).

Conclusion and Next Steps

Decision: Hold

Rationale: While TxGNN assigns a high prediction score and two small historical clinical studies suggest possible symptomatic benefit, there are no registered clinical trials, no confirmed mechanism of action, and the serotonergic rationale is directly contradicted by pharmacovigilance evidence showing SSRIs can induce/worsen RLS. Combined with a blocking gap in TFDA/FDA warning and contraindication data, the evidence base is insufficient to proceed.

To proceed, the following is needed:

TFDA/FDA package insert warnings and contraindications (blocking gap — required before any safety pre-assessment can begin)
Confirmed mechanism of action data (DrugBank API query)
A modern, adequately powered RCT of tryptophan or 5-HTP specifically in RLS patients
Mechanistic clarification of the apparent contradiction between serotonergic RLS induction (SSRIs) and the proposed serotonergic benefit of tryptophan
Review of the 1989 eosinophilia-myalgia syndrome contamination history and current manufacturing/purity controls before considering any therapeutic use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.